BTX News and Press, Brooklyn ImmunoTherapeutics Inc.

Brooklyn ImmunoTherapeutics ( NASDAQ: BTX ) said on Tuesday that it was changing its name to Eterna Therapeutics Inc. to reflect its focus on developing therapies using its patented in-licensed mRNA cell engineering technologies. The name change will be effec...

New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...

A phase 2 trial of Brooklyn ImmunoTherapeutics' ( NASDAQ: BTX ) head and neck cancer candidate IRX-2 showed that the treatment tended to benefit patients more with later stage disease compared to those with earlier stages. The primary endpoint of the study was to esti...

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said it had received a notice from the Nasdaq stating that it was not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq rule. The Company has 180 calendar days from the date of the Notice, or December 14 to rega...

SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system f...

Brooklyn ImmunoTherapeutics (NASDAQ:BTX) on Monday has announced the appointment of Matt Angel as its interim chief executive officer and president.  He will replace current CEO and President Howard J. Federoff, who departs to focus on building a new venture. Matt Ang...

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system fo...

SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and...